Advertisement
+ News Categories + Corporate Categories + Report Categories

Japanese approval for Mitsubishi Tanabe's teneligliptin

13:27 EDT 29 Jun 2012 | BioCentury

Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508) said Japan's Ministry of Health, Labor and Welfare approved a regulatory application for Tenelia teneligliptin to treat Type II diabetes. Mitsubishi plans to market the dipeptidyl peptidase-4 (D..

Related Biotechnology, Pharmaceutical and Healthcare News

Original Article: Japanese approval for Mitsubishi Tanabe's teneligliptin

NEXT ARTICLE

More From BioPortfolio on "Japanese approval for Mitsubishi Tanabe's teneligliptin"

Biotech & Healthcare Channels World News Life Science Events Corporate Database Market Reports Categories
Search BioPortfolio:

Clinical Trials - Daily Updated Database search the latest medical and pharmaceutical trials.

Drugs Database search our comprehensive database of prescription drugs.

Research Literature - Daily Updated Database search biomedical papers and journals.
Advertisement

News Quicklinks

Search Biotech, Medical and Healthcare News

Popular Biotech, Medical and Healthcare News

Biotech News by Article Type

Biotech News by Location

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches

Advertisement

Searches Linking to this Story

mitsubishi tanabe teneligliptin, tenelia teneligliptin, teneligliptin approv japan 2012 june, teneligliptin japan, teneligliptin japan approval, teneligliptin japan, teneligliptin mitsubishi, teneligliptin japan, teneligliptin US FDA approval, teneligliptin approved, teneligliptin japan patent, teneligliptin japan, teneligliptin, teneligliptin approval at japan, Teneligliptin Japanese + Specification & CO

Latest Biotechnology, Pharmaceutical and Healthcare News

Infographic: The Dawn of a New Era for Airborne Infection Control Technology

EyeMed Vision Care Announces Updated Business Model

Initial Study Results Published in American Heart Association’s Stroke Journal Reveal That the Bioness L300 Produces Significant Walking Improvements and is Preferred by Stroke Survivors with Foot Drop

LanguageLine Solutions Launches LanguageUc – Video Interpreting Over Mobile Devices to Provide a Cost-Effective Alternative to Onsite Interpreting

Takeda and Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival with ADCETRIS® (brentuximab vedotin) Versus Prior Therapy at the International Conference on Malignant Lymphoma

Addition of obinutuzumab or rituximab to chlorambucil improves outcomes for chronic lymphocytic leukaemia

Fibrocell Science to Join Russell Indexes